SOPHiA GENETICS SA (SOPH) Stock

Healthcare · Health Information Services · Member of Other US Stocks

SOPHiA GENETICS SA (SOPH) closed at USD 7.06 on 2026-10-14, a change of +72.6 % over the past year, with a market capitalization of USD 620.58M.

SOPHiA GENETICS SA recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

SOPHiA GENETICS SA key figures

Previous close

USD 7.06 (2026-10-14)

1-year change

+72.6 %

Market cap

USD 620.58M

Enterprise value

USD 574.74M

P/E ratio (trailing)

-6.13

P/E ratio (forward)

-14.58

EPS (trailing)

-1.19

EPS (forward)

-0.50

PEG ratio

n/a

Price to book

7.47

Revenue growth

27.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.67

Employees

415

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About SOPHiA GENETICS SA

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for SOPHiA GENETICS SA and compare it with other stocks.